Art. -Nr.: HY-19323

Copy Link Print Information

Ceralasertib

(Synonyms: AZD6738)

68 Cited Publications

Kundenbewertung

Based on 68 publication(s) in Google Scholar

Ceralasertib (AZD6738) is an orally active and bioavailable inhibitor of ATR kinase with an IC₅₀ of 1 nM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.43%
CAS. Nr.: 1352226-88-0
Formel: C₂₀H₂₄N₆O₂S
Molecular Weight:412.51

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Ceralasertib Chemical Structure

CAS. Nr.: 1352226-88-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (68)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Ceralasertib (AZD6738) is an orally active and bioavailable inhibitor of ATR kinase with an IC₅₀ of 1 nM.

IC₅₀ & Target^[1]

ATR

1 nM (IC₅₀)

PI3Kδ

6.8 μM (IC₅₀)

DYRK

10.8 μM (IC₅₀)

Alle ATM/ATR Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.62 μM Compound: 5; AZD6738	Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]
A549	IC₅₀	2 μM Compound: AZD6738	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay	[PMID: 35191694]
CAPAN-1	IC₅₀	5.54 μM Compound: 5; AZD6738	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]
DLD-1	IC₅₀	5.28 μM Compound: 5; AZD6738	Antiproliferative activity against human DLD-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human DLD-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]
Granta-519	IC₅₀	0.55 μM Compound: 5; AZD6738	Antiproliferative activity against human Granta-519 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human Granta-519 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]
HCT-116	IC₅₀	1.12 μM Compound: 5; AZD6738	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]
HCT-116	IC₅₀	3.62 μM Compound: AZD6738	Antiproliferative activity against human HCT-116 cells expressing wildtype ATM incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HCT-116 cells expressing wildtype ATM incubated for 72 hrs by CCK8 assay	[PMID: 38325007]
HT-29	GI₅₀	2.6 μM Compound: 2; AZD6738	Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay	[PMID: 30346772]
HT-29	IC₅₀	2.59 μM Compound: 5; AZD6738	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]
LoVo	GI₅₀	0.44 μM Compound: 2; AZD6738	Cytotoxicity against human LoVo cells after 72 hrs by MTS assay Cytotoxicity against human LoVo cells after 72 hrs by MTS assay	[PMID: 30346772]
LoVo	IC₅₀	0.83 μM Compound: AZD6738	Antiproliferative activity against ATM deficient human LoVo cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against ATM deficient human LoVo cells incubated for 72 hrs by CCK8 assay	[PMID: 38325007]
LoVo	IC₅₀	1.14 μM Compound: 5; AZD6738	Antiproliferative activity against human LoVo cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human LoVo cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]
LoVo	IC₅₀	377 nM Compound: 2	Cytotoxicity against human LoVo cells assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo assay Cytotoxicity against human LoVo cells assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo assay	[PMID: 38299539]
NCI-H446	IC₅₀	1.96 μM Compound: 5; AZD6738	Antiproliferative activity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]
OCI-Ly10	IC₅₀	0.52 μM Compound: 5; AZD6738	Antiproliferative activity against human OCI-Ly10 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human OCI-Ly10 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]
PC-3	IC₅₀	11.28 μM Compound: 5; AZD6738	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]
SUD4	IC₅₀	2.26 μM Compound: 5; AZD6738	Antiproliferative activity against human SU-DHL-4 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human SU-DHL-4 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 39053006]

In Vitro

Ceralasertib (AZD6738) is a potent inhibitor of ATR kinase activity with an IC₅₀ of 0.001 μM against the isolated enzyme and 0.074 μM against ATR kinase-dependent CHK1 phosphorylation in cells. Ceralasertib (AZD6738) induces cell death and senescence in non-small cell lung cancer (NSCLC) cell lines. Ceralasertib (AZD6738) impairs viability of four Kras mutant cell lines: H23, H460, A549, and H358. , with the lowest GI₅₀ and greatest maximal inhibition in H460 and H23 cells (1.05 μM, 88.0% and 2.38 μM, 86.2%, respectively). Ceralasertib (AZD6738) potentiates the cytotoxicity of CDDP and NSC 613327 in NSCLC cell lines with intact ATM kinase signaling, and potently synergizes with CDDP in ATM-deficient NSCLC cells^[1]. Ceralasertib (AZD6738) inhibits human breast cancer cell lines with IC₅₀ values less than 1 μM using MTT assay. Ceralasertib (AZD6738) induces cell cycle arrest and apoptosis. It downregulates DNA damage response molecules and cell proliferative signaling molecules^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Daily administration of Ceralasertib (AZD6738) and ATR kinase inhibition for 14 consecutive days is tolerated in mice and enhances the therapeutic efficacy of CDDP in xenograft models. Remarkably, the combination of CDDP and Ceralasertib (AZD6738) resolves ATM-deficient lung cancer xenografts^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1352226-88-0
Appearance Solid
Molecular Weight 412.51
Formel C₂₀H₂₄N₆O₂S
Color Off-white to light brown
SMILES

O=[S@@](C1(CC1)C2=NC(C3=C4C(NC=C4)=NC=C3)=NC(N5CCOC[C@H]5C)=C2)(C)=N
Synonyms

AZD6738
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (68)

All WBIn Vivo Efficacy StudyIF

Sort by:

Journal Impact Factor

Science

Different repair pathways support intact or truncated insertions by R2 retrotransposon protein. [Abstract]

2026 Feb 26;391(6788):eadz3121. PMID: 41231928
Cancer Commun (Lond)

Radiotherapy-resistant prostate cancer cells escape immune checkpoint blockade through the senescence-related ataxia telangiectasia and Rad3-related protein. [Abstract]

2025 Mar;45(3):218-244. PMID: 39698847
Nat Commun

Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer. [Abstract]

2026 Feb 25;17(1):3142. PMID: 41735312
Nat Commun

PAF1c links S-phase progression to immune evasion and MYC function in pancreatic carcinoma. [Abstract]

2024 Feb 16;15(1):1446. PMID: 38365788

Ceralasertib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Feb 16;15(1):1446. [Abstract]

Immunoblot of KPC cells harboring doxycycline-inducible shRNA targeting luciferase, components of the PAF1c and MYC. Depletion was induced by doxycycline addition for 72 h and AZD6738 treatment for 72 h at 0.2 µM concentration. * refers to a non-specific band. Beta-actin was loading control (n=3).

Ceralasertib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Feb 16;15(1):1446. [Abstract]

pKAP1(S824) intensity upon incubation with AZD6738 (0.1 µM; 24 h) (number of KPC cells plotted: siNTC: n=1654; siCDC73:n=1175).Scale bar: 10 µm. siRNA transfection was 48 h and EdU was added 30 minutes before fixation.
Nat Commun

TP53-dependent toxicity of CRISPR/Cas9 cuts is differential across genomic loci and can confound genetic screening. [Abstract]

2022 Aug 4;13(1):4520. PMID: 35927263

Ceralasertib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Aug 4;13(1):4520. [Abstract]

ATR inhibitor AZD6738 prevent NCI‐H929 TP53^−/− cell growth in NSG mice. NSG mice were subcutaneously injected with 10⁶ NCI‐H929 TP53^−/− cells (left panel). After 1 week, mice with detectable tumors were randomly distributed into four groups of seven mice and treated with AZD6738 (25 mg/kg; i.g., 5 times a week for 2 weeks), as indicated by the arrows (middle panel). The graphs represent the tumor volume kinetics (mean±SD, middle panel) and the tumor volume on Day 12 (right panel).
Nat Commun

Treacle controls the nucleolar response to rDNA breaks via TOPBP1 recruitment and ATR activation. [Abstract]

2020 Jan 8;11(1):123. PMID: 31913317
Redox Biol

Rapid phosphorylation of glucose-6-phosphate dehydrogenase by casein kinase 2 sustains redox homeostasis under ionizing radiation. [Abstract]

2023 Sep:65:102810. PMID: 37478541
Mol Cell

SLFN11-mediated ribosome biogenesis impairment induces TP53-independent apoptosis. [Abstract]

2025 Mar 6;85(5):894-912.e10. PMID: 39909041
Mol Cell

The MYCN oncoprotein is an RNA-binding accessory factor of the nuclear exosome targeting complex. [Abstract]

2024 Jun 6;84(11):2070-2086.e20. PMID: 38703770
Nucleic Acids Res

Human REV1 interacts with DHX36 to promote replication and tolerance of G-quadruplex DNA. [Abstract]

2026 Jun 8;54(11):gkag562. PMID: 42258547
Nucleic Acids Res

ATR phosphorylates DHX9 at serine 321 to suppress R-loop accumulation upon genotoxic stress. [Abstract]

2024 Jan 11;52(1):204-222. PMID: 37930853

Ceralasertib purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2024 Jan 11;52(1):204-222. [Abstract]

AZD6738 (1 μM) were administered for 30 minutes prior to UV irradiation (20 J/m²). HeLa cells were allowed to recover for 2 h after UV treatment, and phosphorylation of DHX9, Chk1, Chk2, and RPA32 was assessed by Western blot with indicated antibodies.
J Exp Clin Cancer Res

DNA damaging agents boost the transcription of endothelin A receptor in high-grade serous ovarian cancer. [Abstract]

2025 Dec 6;45(1):12. PMID: 41350901
J Exp Clin Cancer Res

MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma. [Abstract]

2023 Aug 21;42(1):214. PMID: 37599362
J Exp Clin Cancer Res

ARPC1B promotes mesenchymal phenotype maintenance and radiotherapy resistance by blocking TRIM21-mediated degradation of IFI16 and HuR in glioma stem cells. [Abstract]

2022 Nov 16;41(1):323. PMID: 36380368

Ceralasertib purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2022 Nov 16;41(1):323. [Abstract]

Ceralasertib (AZD6738; 1, 2 µM) signifcantly decreases the protein levels of ATR, IFI16 and HuR in a dose-dependent manner in GSC 267 and GSC 20 cells.
Adv Sci (Weinh)

EccDNA-Driven VPS41 Amplification Alleviates Genotoxic Stress via Lysosomal KAI1 Degradation. [Abstract]

2025 Jul;12(25):e2501934. PMID: 40271553
Cell Rep Med

Targeting RNase H2: A dual-mechanism strategy to elevate replication stress, DNA damage, and antitumor immunity in TNBC. [Abstract]

2026 May 19;7(5):102750. PMID: 42013846
Sci Adv

Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities. [Abstract]

2026 Jun 26;12(26):eadz3351. PMID: 42361179
Cardiovasc Res

Telomere recapping prevents pathogenic telomere-to-mitochondrial DNA communication in heart failure. [Abstract]

2026 May 22;122(7):935-952. PMID: 41942104
Cell Death Dis

TRIB2 modulates proteasome function to reduce ubiquitin stability and protect liver cancer cells against oxidative stress. [Abstract]

2021 Jan 7;12(1):42. PMID: 33414446
Cancer Lett

2026 Feb 4;642:218300.
Cancer Lett

Targeting ATR signaling in sarcoma with homologous recombination deficiency. [Abstract]

2026 Apr 1:642:218300. PMID: 41651400
Hemasphere

Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53-deficient myeloma cells. [Abstract]

2024 Oct 8;8(10):e70016. PMID: 39380841
Phytother Res

Lutein inhibits tumor progression through the ATR/Chk1/p53 signaling pathway in non-small cell lung cancer. [Abstract]

2023 Apr;37(4):1260-1273. PMID: 37041670
Br J Cancer

PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes. [Abstract]

2024 Jul;131(2):231-242. PMID: 38806724
Cell Rep

POLθ processes ssDNA gaps and promotes replication fork progression in BRCA1-deficient cells. [Abstract]

2022 Nov 29;41(9):111716. PMID: 36400033
Cell Rep

ATR Restrains DNA Synthesis and Mitotic Catastrophe in Response to CDC7 Inhibition. [Abstract]

2020 Sep 1;32(9):108096. PMID: 32877678
Cell Rep

FBXW7 Confers Radiation Survival by Targeting p53 for Degradation. [Abstract]

2020 Jan 14;30(2):497-509.e4. PMID: 31940492
J Med Chem

Discovery of a Meisoindigo-Derived PROTAC as the ATM Degrader: Revolutionizing Colorectal Cancer Therapy via Synthetic Lethality with ATR Inhibitors. [Abstract]

2024 May 9;67(9):7620-7634. PMID: 38634707
J Med Chem

Discovery of Ruthenium(II) Metallocompound and Olaparib Synergy for Cancer Combination Therapy. [Abstract]

2023 May 25;66(10):6922-6937. PMID: 37185020
Sci Signal

Metabolically inducing defects in DNA repair sensitizes BRCA-wild-type cancer cells to replication stress. [Abstract]

2024 Nov 12;17(862):eadl6445. PMID: 39531517
PLoS Biol

Loss of the abasic site sensor HMCES is synthetic lethal with the activity of the APOBEC3A cytosine deaminase in cancer cells. [Abstract]

2021 Mar 31;19(3):e3001176. PMID: 33788831
JCI Insight

AURKA inhibitor VIC-1911 induces mitotic defects and functional BRCAness, sensitizing prostate cancer to PARP inhibition. [Abstract]

2026 Mar 31:e196665. PMID: 41915443
J Cell Biol

DNA damage promotes microtubule dynamics through a DNA-PK-AKT axis for enhanced repair. [Abstract]

2021 Feb 1;220(2):e201911025. PMID: 33404607
J Am Heart Assoc

Replication Stress Response Modifies Sarcomeric Cardiomyopathy Remodeling. [Abstract]

2021 Aug 3;10(15):e021768. PMID: 34323119
EMBO Rep

CDC7 kinase promotes MRE11 fork processing, modulating fork speed and chromosomal breakage. [Abstract]

2020 Aug 5;21(8):e48920. PMID: 32496651
Oncogenesis

SCFβ-TrCP-mediated degradation of TOP2β promotes cancer cell survival in response to chemotherapeutic drugs targeting topoisomerase II. [Abstract]

2020 Feb 3;9(2):8. PMID: 32015321
Mol Cancer Res

Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2. [Abstract]

2020 Jan;18(1):91-104. PMID: 31649026
Inflammation

AZD6738 Attenuates LPS-Induced Corneal Inflammation and Fibrosis by Modulating Macrophage Function and Polarization. [Abstract]

2025 Feb 4. PMID: 39903421
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Am J Pathol

Low-Dose Radiotherapy Attenuates Pulmonary Granulomas Involving Ataxia-Telangiectasia Mutated-Dependent Modulation of the Interferon-β Response: A Host-Directed Therapeutic Strategy for Tuberculosis. [Abstract]

2026 Jun 10:S0002-9440(26)00163-X. PMID: 42270072
Int J Cancer

Enhanced pharmacological activities of AKR1C3-activated prodrug AST-3424 in cancer cells with defective DNA repair. [Abstract]

2025 Jan 15;156(2):417-430. PMID: 39243400
Transl Oncol

MTA2 sensitizes gastric cancer cells to PARP inhibition by induction of DNA replication stress. [Abstract]

2021 Oct;14(10):101167. PMID: 34280886
Cell Signal

MYC amplification sensitizes TNBC to CHK1 inhibitors. [Abstract]

2025 Jul:131:111709. PMID: 40037423
Oncol Rep

AZD6738 promotes the tumor suppressive effects of trifluridine in colorectal cancer cells. [Abstract]

2023 Mar;49(3):52. PMID: 36734271
Neurooncol Adv

Ion channel modulator DPI-201-106 significantly enhances antitumor activity of DNA damage response inhibitors in glioblastoma. [Abstract]

2024 Nov 19;6(1):vdae187. PMID: 39659830
J Biol Chem

The E3 ligase β-TRCP1 earmarks OTUD3 for destruction to fine-tune cGAS activation. [Abstract]

2026 Jun;302(6):111461. PMID: 41999888
Biomed Res Int

ATR Inhibitor Synergizes PARP Inhibitor Cytotoxicity in Homologous Recombination Repair Deficiency TK6 Cell Lines. [Abstract]

2023 Feb 6:2023:7891753. PMID: 36794257
Mol Cell Biol

Kinase Inhibitor-Induced Cell-Type Specific Vacuole Formation in the Absence of Canonical ATG5-Dependent Autophagy Initiation Pathway. [Abstract]

2025;45(3):99-115. PMID: 39895059
J Ocul Pharmacol Ther

Exploring the Efficacy of AZD6738 in Corneal Neovascularization: Autophagy Enhancement and Angiogenesis Inhibition. [Abstract]

2025 Jun 27. PMID: 40576624
Oncol Lett

DNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines. [Abstract]

2025 Jan 7;29(3):128. PMID: 39822940
bioRxiv

Oxidative DNA lesions destabilize centromeres and drive chromosome instability. [Abstract]

2026 May 1:2026.04.28.717272. PMID: 42094395
bioRxiv

2025 Dec 9.
bioRxiv

2025 Oct 15.
bioRxiv

ATM promotes reversed fork processing during DNA interstrand cross-link repair. [Abstract]

2025 Oct 9:2025.10.08.680157. PMID: 41279244
Res Sq

2025 Oct 1.
bioRxiv

2025 Aug 31.
bioRxiv

An ATM-PPM1D Circuit Controls the Processing and Restart of DNA Replication Forks. [Abstract]

2025 May 15:2025.05.13.652823. PMID: 40462982
bioRxiv

2025 April 17.
bioRxiv

PAIRWISE: Deep Learning-based Prediction of Effective Personalized Drug Combinations in Cancer. [Abstract]

2024 Nov 6:2024.11.04.621884. PMID: 39574568
Norges teknisk-naturvitenskapelige universitet

2024.
biorxiv

2024 Jun 03.
bioRxiv

2024 Mar 28.
bioRxiv

2024 Apr 25.
SSRN

2023 Aug 30.
SSRN

2023 Jul 24.
Research Square Preprint

2023 Jun 9.
Technische Universitat Darmstadt

2022 Aug.
University of London

2021 Sep.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 70 mg/mL (169.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4242 mL

12.1209 mL

24.2418 mL

5 mM

0.4848 mL

2.4242 mL

4.8484 mL

10 mM

0.2424 mL

1.2121 mL

2.4242 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (12.12 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (5.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 10 mg/mL (24.24 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

Ceralasertib (AZD6738) is dissolved in DMSO at 30 mM and diluted in DMSO to desired working concentrations. The final DMSO concentration in media for all conditions and controls is 0.1% for Ceralasertib (AZD6738) dose response experiments, 0.05% for Ceralasertib (AZD6738) + chemotherapy viability experiments, and 0.025% for all experiments involving 0.3 μM and 1.0 μM doses of Ceralasertib (AZD6738)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice^[1]
Ceralasertib (AZD6738) is dissolved in DMSO at a concentration of 25 mg/mL or 50 mg/mL and diluted 1:5 in propylene glycol. Ceralasertib (AZD6738) is administered by oral gavage at 25 mg/kg (H23) or 50 mg/kg (H460) for 14 consecutive days. The dosing volume is 10 mL/kg.^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Vendetti FP, et al. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of CDDP to resolve ATM-deficient non-small cell lung cancer in vivo. [Content Brief]

[2]. Kim HJ, et al. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells. Int J Cancer. 2017 Jan 1;140(1):109-119. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4242 mL	12.1209 mL	24.2418 mL	60.6046 mL
	5 mM	0.4848 mL	2.4242 mL	4.8484 mL	12.1209 mL
	10 mM	0.2424 mL	1.2121 mL	2.4242 mL	6.0605 mL
	15 mM	0.1616 mL	0.8081 mL	1.6161 mL	4.0403 mL
	20 mM	0.1212 mL	0.6060 mL	1.2121 mL	3.0302 mL
	25 mM	0.0970 mL	0.4848 mL	0.9697 mL	2.4242 mL
	30 mM	0.0808 mL	0.4040 mL	0.8081 mL	2.0202 mL
	40 mM	0.0606 mL	0.3030 mL	0.6060 mL	1.5151 mL
	50 mM	0.0485 mL	0.2424 mL	0.4848 mL	1.2121 mL
	60 mM	0.0404 mL	0.2020 mL	0.4040 mL	1.0101 mL
	80 mM	0.0303 mL	0.1515 mL	0.3030 mL	0.7576 mL
	100 mM	0.0242 mL	0.1212 mL	0.2424 mL	0.6060 mL

Keywords

Ceralasertib

68 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Ceralasertib

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Glucose Metabolism Compound Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) Ceralasertib

Alle ATM/ATR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (68)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Ceralasertib Related Classifications

HY-19323 Related Classifications